Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

46 results about "Cannabinoid receptor ligand" patented technology

Novel compounds as cannabinoid receptor ligands

Disclosed herein are cannabinoid receptor ligands of formula (I)wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Owner:ABBVIE INC

Novel compounds as cannabinoid receptor ligands

Disclosed herein are cannabinoid receptor ligands of formula (I)wherein L1, A1, R1g, z, R2, R3, and R4 are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Owner:ABBVIE INC

Novel compounds as cannabinoid receptor ligands

The present application relates to cannabinoid receptor ligands of formula (I)wherein X1, A1, Rx, R2, R3, R4, and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.
Owner:ABBVIE INC

Novel compounds as cannabinoid receptor ligands

Disclosed herein are cannabinoid receptor ligands of formula (I)wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Owner:ABBVIE INC

Imidazole compounds and uses thereof

InactiveUS20050026983A1Not affect characteristicBiocideOrganic active ingredientsDiseaseBiochemistry
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the activation of the cannabinoid receptors in animals are described herein.
Owner:PFIZER INC

Compounds as cannabinoid receptor ligands

Disclosed herein are cannabinoid receptor ligands of formula (I)wherein Y, X1, X2, X3, R1, and R2 are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Owner:ABBVIE INC

Compounds as cannabinoid receptor ligands

Disclosed herein are cannabinoid receptor ligands of formula (I)wherein Ring A and R1 are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also described.
Owner:ABBVIE INC

Compounds as cannabinoid receptor ligands

Disclosed herein are cannabinoid receptor ligands of formula (I)wherein A1 and Rx are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Owner:ABBVIE INC

Compounds as cannabinoid receptor ligands

Cannabinoid receptor ligands of formula (I)wherein Ring A and R1 are as defined in the specification. Compositions including such compounds, and methods of treating conditions and disorders using such compounds and compositions are also described.
Owner:ABBVIE INC

Bicyclic CB2 cannabinoid receptor ligands

InactiveUS20050020544A1BiocideNervous disorderCannabinoid Receptor CB2Autoimmune disease
The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) alpha-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neurophathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.
Owner:PHARMOS

Proline analogs as ligands for cannabinoid receptors

The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or preventing a Condition comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof.
Owner:PURDUE PHARMA LP

Cannabinoid receptor ligands and uses thereof

Compounds of Formula (I) and (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
Owner:PFIZER PRODS ETAT DE CONNECTICUT

Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation

The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor.
Owner:GLENMARK PHARMA SA

Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation

InactiveUS20080200501A1Suitable for treatmentReducing tobacco cravingBiocideSenses disorderDiseaseCannabinoid
The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMA SA

Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation

The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMA SA

Methods of treatment of inflammation of the gut

Described herein are methods of improving immune homeostasis in the gut of a subject suffering from an autoimmune disease characterized by inflammation of the gut by administering, e.g., orally administering, to the subject an effective amount of a cannabinoid receptor agonist to improve immune homeostasis in the gut of the subject. Exemplary cannabinoid receptor ligands include Anandamide. The methods are particularly useful to treat gut inflammation associated with diabetes mellitus Type I.
Owner:UNIV OF CONNECTICUT

Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation

The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenerative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMA SA

Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation

The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMACEUTICALS LIMITED

Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation

The present invention relates to novel cannabinoid receptor modulators, in particular cannahinoid I (CB1) or cannabinoid 2 (CH2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenerative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMACEUTICALS LIMITED

Bicyclic CB2 cannabinoid receptor ligands

The present invention relates to atypical cannabinoids, i.e. ligands of the peripheral cannabinoid receptor CB2, and pharmaceutical compositions thereof comprising novel (+) α-pinene derivatives as active ingredients, which are useful in the prophylaxis of and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, type I diabetes, hepatitis, psoriasis and immune Associated disorders, including but not limited to tissue rejection in organ transplantation, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, including peripheral, visceral, neurological Sexual, inflammatory and associated pain, muscle spasms, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, nervous system disorders including stroke, migraine and cluster headaches, including Parkinson's disease, Neurodegenerative diseases like Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, prion-related neurodegeneration, CNS poisoning, and certain types of cancer.
Owner:PHARMOS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products